Florida Cerebrovascular Disease Biorepository and Genomics Center

Creating a Florida Cerebrovascular Disease Biorepository and Genomics Center

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05491980

Enrollment

Registered

2022-08-08

Start date

2022-08-02

Completion date

2030-06-01

Last updated

2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysmal Subarachnoid Hemorrhage, Anoxic Brain Injury, Arteriovenous Fistula, Asymptomatic Carotid Artery Stenosis, CADASIL, Carotid Artery Stenosis Symptomatic, Cerebral Venous Thrombosis, Cerebrovascular Disease, Fibromuscular Dysplasia, Intracerebral Hemorrhage, Ischemic Stroke, Leukoaraiosis, Moyamoya Disease, Non-Aneurysmal Perimesencephalic Subarachnoid Haemorrhage, Reversible Cerebral Vasoconstriction Syndrome, Subarachnoid Hemorrhage, Transient Ischemic Attack, Unruptured Intracranial Aneurysm, Vascular Dementia

Brief summary

The purpose of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida, which will include collecting medical history information and blood from subjects affected by cerebrovascular disease. The information and blood samples collected may be used in future research for the study of cerebrovascular disease and to learn about, prevent or treat other health problems.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

• Affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid hemorrhage, leukoaraiosis, arteriovenous fistula, reversible cerebral vasoconstriction syndrome (RCVS), and CADASIL.

Exclusion criteria

• All patients with the following known or suspected virulent microorganisms causing an active or latent infection will be excluded from the study: * Human immunodeficiency virus (HIV); * Any viral hepatitis; * West Nile virus (WNV); * Influenza virus; * Tuberculosis (TB); * Any bacteremia; * Any fungemia; * Any prionopathy.

Design outcomes

Primary

Measure	Time frame	Description
Stroke or TIA at 12 months	1 year	Number of participants to experience new diagnosis of TIA or stroke.

Secondary

Measure	Time frame	Description
Modified Rankin Scale	1 year	Measure of overall functional status

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJames Meschia, MD

Mayo Clinic

Outcome results